Patent Issued for Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof (USPTO 11578135).

The multispecific antigen-binding molecule of claim 6, wherein the multispecific antigen-binding molecule is a bispecific antibody. Keywords: Antibodies; Biopharmaceutical Companies; Biopharmaceutical Company; Biotechnology Company; Blood Proteins; Business; Drugs and Therapies; Health and Medicine; Healthcare Biotechnology Companies; Immunoglobulins; Immunology; Peptides; Pharmaceutical Companies; Proteins; Proteomics; Regeneron; Regeneron Pharmaceuticals Inc.; Therapeutics; Therapy EN Antibodies Biopharmaceutical Companies Biopharmaceutical Company Biotechnology Company Blood Proteins Business Drugs and Therapies Health and Medicine Healthcare Biotechnology Companies Immunoglobulins Immunology Peptides Pharmaceutical Companies Proteins Proteomics Regeneron Regeneron Pharmaceuticals Inc. Therapeutics Therapy 2023 MAR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Regeneron Pharmaceuticals Inc. (Tarrytown, New York, United States) has been issued patent number 11578135, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]